Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Ltd., a biotech company focused on intranasal hydrogel technologies, has secured agreements with three major U.S. clinical sites for its upcoming NASARIX™ allergy blocker trial. The multi-center study will evaluate the safety and efficacy of its non-pharmaceutical nasal spray aimed at preventing seasonal allergic rhinitis by physically bl…